Special Collections

Clinician POV

Antipsychotic medications are the most common cause of tardive dyskinesia (TD), a condition that may cause involuntary bodily movements. Vesicular monoamine transporter type 2 (VMAT2) inhibitors represent a treatment option that may reduce the symptoms of this movement disorder. In this article, Joseph Jankovic, MD, professor in the Department of Neurology and director of the Parkinson’s Disease Center and Movement Disorders Clinic at Baylor College of Medicine in Houston, Texas, discusses clinical considerations in the use of VMAT2 inhibitors for the treatment of TD.